NEW YORK — A federal vaccine advisory panel this week is expected to revisit long-standing guidance that all newborns receive a hepatitis B vaccine within 24 hours of birth. The committee, chaired under Health Secretary Robert F. Kennedy Jr., is scheduled to discuss a change at a Thursday meeting that would depart from decades of public-health advice. Medical groups including the American Academy of Pediatrics say they will continue to recommend the birth dose because it prevents chronic infection and saves lives. The meeting has raised alarms among public-health officials, state leaders and some members of Congress over potential increases in infant infections.
Key takeaways
- The Advisory Committee on Immunization Practices (ACIP) is meeting Thursday to consider altering the current U.S. recommendation that a hepatitis B vaccine be given to medically stable newborns within 24 hours of birth.
- Hepatitis B can become chronic in roughly 90% of infants who are infected, raising risks of liver failure, cirrhosis and liver cancer later in life.
- An estimated 2.4 million people in the United States have hepatitis B and up to half may be unaware of their infection, according to the CDC.
- The birth dose policy dates to a 1991 ACIP recommendation; current guidance calls for a first dose within 24 hours for infants weighing at least 4.4 pounds (2 kilograms), with additional doses at about 1 and 6 months.
- Public-health analyses, including a Vaccine Integrity Project review of more than 400 studies across 40 years, conclude the birth-dose is safe and helped reduce pediatric cases from ~18,000 to ~2,200 annually over roughly 30 years.
- A non–peer-reviewed projection circulated this week estimates delaying the first dose to 2 months could lead to at least 1,400 pediatric infections and 480 deaths.
- ACIP’s influence affects programs such as Vaccines for Children, but hospital practice and billing have often maintained newborn hepatitis B administration regardless of ACIP wording.
Background
Hepatitis B is a viral infection that primarily affects the liver. In many adults the acute illness resolves within months, but when infants are infected the virus frequently persists, producing chronic infection that can later cause liver failure, cirrhosis and hepatocellular carcinoma. Transmission routes in adults typically include sexual contact and sharing injection equipment; another key route is mother-to-child transmission during childbirth.
Scientific breakthroughs that led to current prevention tools date back decades: federal scientist Baruch Blumberg identified the virus in 1965 and later received the Nobel Prize for that work, which paved the way for diagnostic tests and vaccines. The first hepatitis B vaccine was licensed in the United States in 1981. In 1991, ACIP recommended giving the first vaccine dose at birth to reduce missed exposures from untested or false-negative maternal screening and to limit household transmission, since the virus can survive on surfaces for over a week.
Over subsequent decades the early-dose strategy is widely credited with sharp reductions in pediatric hepatitis B. Routine infant vaccination programs, combined with maternal screening and follow-up doses at about 1 and 6 months, became standard practice in U.S. hospitals and clinics.
Main event
This week ACIP — the government-appointed panel whose guidance typically becomes national practice — is reviewing the birth-dose recommendation. Earlier this year Health Secretary Robert F. Kennedy Jr. replaced the committee’s 17 members with a new slate that includes several figures who have previously expressed skepticism about certain vaccines. At a September meeting members raised questions about the timing and consent around giving an immunization during the immediate newborn period.
Committee member Dr. Evelyn Griffin asked whether giving the vaccine at birth asks “our babies to solve an adult problem,” a line of questioning that signals a shift from safety concerns to debates over parental consent and public trust. Another member, Dr. Robert Malone, framed the issue as one rooted in trust rather than a safety signal, saying some parents are uncomfortable with a unilateral medical action at birth without extensive informed consent.
The committee postponed a final vote in September but listed the item for action on Thursday’s agenda. Federal officials have not disclosed the exact alternative timing under consideration or the body of evidence they will cite. That opacity has prompted responses from pediatric societies, public-health researchers and state officials urging the panel not to roll back the birth-dose guidance.
Analysis & implications
Changing ACIP guidance on the birth dose would have layered effects: clinical, programmatic and societal. Clinically, delaying the first dose increases the window in which an infant exposed at birth or shortly thereafter could become infected and progress to chronic disease. Because infants who contract hepatitis B have roughly a 90% chance of lifelong infection, even small increases in newborn transmission translate into meaningful future burdens of liver disease.
Programmatically, ACIP’s recommendations influence what vaccines are covered by federal programs such as Vaccines for Children. However, the practical impact on immediate hospital practice may be muted: many hospitals bundle the hepatitis B shot into newborn care and billing, and insurers and state programs often reimburse the vaccine whether or not ACIP text changes. That may blunt abrupt changes in administration rates but would not eliminate confusion among clinicians and families.
Politically and socially, the review has become a flashpoint. It follows major personnel changes at ACIP and reflects broader tensions over vaccine policy, parental rights and public trust. A visible change in guidance risks fueling social media spread of alarm and misinformation; public-health leaders warn that any perceived weakening of the recommendation could reduce uptake and reverse decades of progress.
Economically the downstream costs of additional chronic infections are substantial: lifelong monitoring, antiviral therapy for some patients, and increased cases of end-stage liver disease and cancer. Public-health modelers who examined a scenario delaying the birth dose to 2 months projected hundreds of avoidable deaths and thousands of infections — a projection that, if borne out, would have long-term health-system and fiscal consequences.
Comparison & data
| Metric | Historical figure | Current/Note |
|---|---|---|
| Estimated U.S. people with hepatitis B | 2.4 million | Up to half unaware (CDC) |
| Pediatric annual cases (approx.) | ~18,000 (pre-vaccine era) | ~2,200 (after ~30 years of infant vaccination) |
| Key dates | 1965 discovery; 1981 vaccine license; 1991 ACIP birth-dose recommendation | Current guidance: birth dose within 24 hours for infants ≥4.4 lb (2 kg) |
The table summarizes the long-term decline in pediatric hepatitis B cases since routine newborn vaccination and highlights the diagnostic and regulatory milestones. While ACIP guidance shapes national practice, local hospital workflows, state policies and federal programs also determine whether changes in wording translate into changes in coverage or administration.
Reactions & quotes
Public-health groups have reacted strongly. The American Academy of Pediatrics said it will continue to recommend the birth dose, emphasizing the vaccine’s role in preventing chronic disease.
“We are going to continue to recommend it because it saves lives.”
Dr. Sean O’Leary, American Academy of Pediatrics
Several committee members framed the debate differently, centering on parental consent and institutional trust rather than an immediate safety signal.
“Are we asking our babies to solve an adult problem?”
Dr. Evelyn Griffin, ACIP member
Some elected officials have urged oversight. Senator Patty Murray called for a congressional hearing to question the Health Secretary about the advisory panel’s actions, characterizing a rollback as putting infants at risk.
“Ending the decades-long recommendation that babies born in the U.S. get vaccinated against hepatitis B is a heartless choice to allow babies to die.”
Sen. Patty Murray (D-WA)
Unconfirmed
- The exact alternative timing that ACIP will vote on Thursday has not been publicly disclosed and remains unconfirmed.
- The specific studies or datasets the committee will rely on to justify any delay have not been listed in the public agenda.
- Models projecting infections and deaths from a delayed schedule are preliminary and some estimates remain unpublished and not peer reviewed.
Bottom line
The pending ACIP discussion represents a potential shift away from a long-standing, broadly accepted public-health practice: administering a first hepatitis B vaccine dose within 24 hours of birth. Medical groups and public-health researchers warn that delaying the birth dose could increase infant infections and long-term liver disease. Even if programmatic or billing practices keep many hospitals administering the shot, a formal change in guidance risks sowing confusion, eroding trust and amplifying vaccine hesitancy.
Policymakers face a choice between preserving a precaution that has demonstrably reduced pediatric hepatitis B or revising guidance in response to concerns about consent and parental comfort. The committee has not released comprehensive new evidence to justify a reversal, and several projections of harm from delays are preliminary. Stakeholders — from clinicians to state leaders to Congress — are watching Thursday’s action closely for both scientific rationale and practical consequences.
Sources
- The Associated Press (news reporting)
- Centers for Disease Control and Prevention (U.S. government public-health information)
- Vaccine Integrity Project (research/analysis group)
- American Academy of Pediatrics (medical association)